Figure 2.

Tornado diagrams for one-way deterministic sensitivity analysis. U_K_PS, utility of pembrolizumab in progression survival state; C_K, cost of pembrolizumab; U_K_PFS, utility of pembrolizumab in progression-free survival state; U_C_PS, utility of chemotherapy in progression survival state; U_C_PFS, utility of chemotherapy in progression-free survival state; C_C_PS, cost of chemotherapy in progression survival state; C_K_PS, cost of pembrolizumab in progression survival state; C-BSC, cost of best support care; C_C, cost of chemotherapy; C_pneumonitis, cost of treatment in pneumonitis; C_O, cost of nivolumab; C_Followup, cost of follow-up; C_anemia, cost of treatment in anemia; C_VEGF, cost of bevacizumab; C_ALK, cost of crizotinib; C_neutropenia, cost of treatment in neutropenia; C_EGFR, cost of epidermal growth factor receptor inhibitors.